<br>
<br>(ii) in the event of a request by an authorized trading partner, in a secure manner that ensures the protection of confidential commercial information and trade secrets, for purposes of investigating a suspect product or assisting the Secretary (or other appropriate Federal or State official) with a request described in clause (i).
<br>
<br>(F) Each person accepting a saleable return shall have systems and processes in place to allow acceptance of such product and may accept saleable returns only if such person can associate the saleable return product with the transaction information and transaction statement associated with that product.
<br>(2) Compliance
<br>(A) Information maintenance agreement
<br>
<br>A dispenser may enter into a written agreement with a third party, including an authorized wholesale distributor, under which the third party shall confidentially maintain any information and statements required to be maintained under this section. If a dispenser enters into such an agreement, the dispenser shall maintain a copy of the written agreement and shall not be relieved of the obligations of the dispenser under this subsection.
<br>(B) Alternative methods
<br>
<br>The Secretary, taking into consideration the assessment conducted under paragraph (3), shall provide for alternative methods of compliance with any of the requirements set forth in paragraph (1), including—
<br>
<br>(i) establishing timelines for compliance by small businesses (including small business dispensers with 25 or fewer full-time employees) with such requirements, in order to ensure that such requirements do not impose undue economic hardship for small businesses, including small business dispensers for whom the criteria set forth in the assessment under paragraph (3) is not met, if the Secretary determines that such requirements under paragraph (1) would result in undue economic hardship; and
<br>
<br>(ii) establishing a process by which a dispenser may request a waiver from any of the requirements set forth in paragraph (1) if the Secretary determines that such requirements would result in an undue economic hardship, which shall include a process for the biennial review and renewal of any such waiver.
<br>(3) Assessment
<br>(A) In general
<br>
<br>Not later than the date that is 18 months after the Secretary issues the final guidance required under subsection (h), the Secretary shall enter into a contract with a private, independent consulting firm with expertise to conduct a technology and software assessment that looks at the feasibility of dispensers with 25 or fewer full-time employees conducting interoperable, electronic tracing of products at the package level. Such assessment shall be completed not later than 8½ years after November 27, 2013.
<br>(B) Condition
<br>
<br>As a condition of the award of the contract under subparagraph (A), the private, independent consulting firm shall agree to consult with dispensers with 25 or fewer full-time employees when conducting the assessment under such subparagraph.
<br>(C) Content
<br>
<br>The assessment under subparagraph (A) shall assess whether—
<br>
<br>(i) the necessary software and hardware is readily accessible to such dispensers;
<br>
<br>(ii) the necessary software and hardware is prohibitively expensive to obtain, install, and maintain for such dispensers; and
<br>
<br>(iii) the necessary hardware and software can be integrated into business practices, such as interoperability with wholesale distributors, for such dispensers.
<br>(D) Publication
<br>
<br>The Secretary shall—
<br>
<br>(i) publish the statement of work for the assessment under subparagraph (A) for public comment prior to beginning the assessment;
<br>
<br>(ii) publish the final assessment for public comment not later than 30 calendar days after receiving such assessment; and
<br>
<br>(iii) hold a public meeting not later than 180 calendar days after receiving the final assessment at which public stakeholders may present their views on the assessment.
<br>(4) Procedure
<br>
<br>Notwithstanding section 553 of title 5, the Secretary, in promulgating any regulation pursuant to this section, shall—
<br>
<br>(A) provide appropriate flexibility by—
<br>
<br>(i) not requiring the adoption of specific business systems for the maintenance and transmission of data;
<br>
<br>(ii) prescribing alternative methods of compliance for any of the requirements set forth in paragraph (1) or set forth in regulations implementing such requirements, including—
<br>
<br>(I) timelines for small businesses to comply with the requirements set forth in the regulations in order to ensure that such requirements do not impose undue economic hardship for small businesses (including small business dispensers for whom the criteria set forth in the assessment under paragraph (3) is not met), if the Secretary determines that such requirements would result in undue economic hardship; and
<br>
<br>(II) the establishment of a process by which a dispenser may request a waiver from any of the requirements set forth in such regulations if the Secretary determines that such requirements would result in an undue economic hardship; and
<br>
<br>(iii) taking into consideration—
<br>
<br>(I) the results of pilot projects, including pilot projects pursuant to this section and private sector pilot projects, including those involving the use of aggregation and inference;
<br>
<br>(II) the public meetings held and related guidance documents issued under this section;
<br>
<br>(III) the public health benefits of any additional regulations in comparison to the cost of compliance with such requirements, including on entities of varying sizes and capabilities;
<br>
<br>(IV) the diversity of the pharmaceutical distribution supply chain by providing appropriate flexibility for each sector, including both large and small businesses; and
<br>
<br>(V) the assessment pursuant to paragraph (3) with respect to small business dispensers, including related public comment and the public meeting, and requirements under this section;
<br>
<br>(B) issue a notice of proposed rulemaking that includes a copy of the proposed regulation;
<br>
<br>(C) provide a period of not less than 60 days for comments on the proposed regulation; and
<br>
<br>(D) publish in the Federal Register the final regulation not less than 2 years prior to the effective date of the regulation.
<br>(h) Guidance documents
<br>(1) In general
<br>
<br>For the purposes of facilitating the successful and efficient adoption of secure, interoperable product tracing at the package level in order to enhance drug distribution security and further protect the public health, the Secretary shall issue the guidance documents as provided for in this subsection.
<br>(2) Suspect and illegitimate product
<br>(A) In general
<br>
<br>Not later than 180 days after November 27, 2013, the Secretary shall issue a guidance document to aid trading partners in the identification of a suspect product and notification termination. Such guidance document shall—
<br>
<br>(i) identify specific scenarios that could significantly increase the risk of a suspect product entering the pharmaceutical distribution supply chain;
<br>
<br>(ii) provide recommendation on how trading partners may identify such product and make a determination on whether the product is a suspect product as soon as practicable; and
<br>
<br>(iii) set forth the process by which manufacturers, repackagers, wholesale distributors, and dispensers shall terminate notifications in consultation with the Secretary regarding illegitimate product pursuant to subsections (b)(4)(B), (c)(4)(B), (d)(4)(B), and (e)(4)(B).
<br>(B) Revised guidance
<br>
<br>If the Secretary revises the guidance issued under subparagraph (A), the Secretary shall follow the procedure set forth in paragraph (5).
<br>(3) Unit level tracing
<br>(A) In general
<br>
<br>In order to enhance drug distribution security at the package level, not later than 18 months after conducting a public meeting on the system attributes necessary to enable secure tracing of product at the package level, including allowing for the use of verification, inference, and aggregation, as necessary, the Secretary shall issue a final guidance document that outlines and makes recommendations with respect to the system attributes necessary to enable secure tracing at the package level as required under the requirements established under subsection (g). Such guidance document shall—
<br>
<br>(i) define the circumstances under which the sectors within the pharmaceutical distribution supply chain may, in the most efficient manner practicable, infer the contents of a case, pallet, tote, or other aggregate of individual packages or containers of product, from a product identifier associated with the case, pallet, tote, or other aggregate, without opening each case, pallet, tote, or other aggregate or otherwise individually scanning each package;
<br>
<br>(ii) identify methods and processes to enhance secure tracing of product at the package level, such as secure processes to facilitate the use of inference, enhanced verification activities, the use of aggregation and inference, processes that utilize the product identifiers to enhance tracing of product at the package level, including the standardized numerical identifier, or package security features; and
<br>
<br>(iii) ensure the protection of confidential commercial information and trade secrets.
<br>(B) Procedure
<br>
<br>In issuing the guidance under subparagraph (A), and in revising such guidance, if applicable, the Secretary shall follow the procedure set forth in paragraph (5).
<br>(4) Standards for interoperable data exchange
<br>(A) In general
<br>
<br>In order to enhance secure tracing of a product at the package level, the Secretary, not later than 18 months after conducting a public meeting on the interoperable standards necessary to enhance the security of the pharmaceutical distribution supply chain, shall update the guidance issued pursuant to subsection (a)(2), as necessary and appropriate, and finalize such guidance document so that the guidance document—
<br>
<br>(i) identifies and makes recommendations with respect to the standards necessary for adoption in order to support the secure, interoperable electronic data exchange among the pharmaceutical distribution supply chain that comply with a form and format developed by a widely recognized international standards development organization;
<br>
<br>(ii) takes into consideration standards established pursuant to subsection (a)(2) and section 355e of this title;
<br>
<br>(iii) facilitates the creation of a uniform process or methodology for product tracing; and
<br>
<br>(iv) ensures the protection of confidential commercial information and trade secrets.
<br>(B) Procedure
<br>
<br>In issuing the guidance under subparagraph (A), and in revising such guidance, if applicable, the Secretary shall follow the procedure set forth in paragraph (5).
<br>(5) Procedure
<br>
<br>In issuing or revising any guidance issued pursuant to this subsection or subsection (g), except the initial guidance issued under paragraph (2)(A), the Secretary shall—
<br>
<br>(A) publish a notice in the Federal Register for a period not less than 30 days announcing that the draft or revised draft guidance is available;
<br>
<br>(B) post the draft guidance document on the Internet Web site of the Food and Drug Administration and make such draft guidance document available in hard copy;
<br>
<br>(C) provide an opportunity for comment and review and take into consideration any comments received;
<br>
<br>(D) revise the draft guidance, as appropriate;
<br>
<br>(E) publish a notice in the Federal Register for a period not less than 30 days announcing that the final guidance or final revised guidance is available;
<br>
<br>(F) post the final guidance document on the Internet Web site of the Food and Drug Administration and make such final guidance document available in hard copy; and
<br>
<br>(G) provide for an effective date of not earlier than 1 year after such guidance becomes final.
<br>(i) Public meetings
<br>(1) In general
<br>
<br>The Secretary shall hold not less than 5 public meetings to enhance the safety and security of the pharmaceutical distribution supply chain and provide for comment. The Secretary may hold the first such public meeting not earlier than 1 year after November 27, 2013. In carrying out the public meetings described in this paragraph, the Secretary shall—
<br>
<br>(A) prioritize topics necessary to inform the issuance of the guidance described in paragraphs (3) and (4) of subsection (h); and
<br>
<br>(B) take all measures reasonable and practicable to ensure the protection of confidential commercial information and trade secrets.
<br>(2) Content
<br>
<br>Each of the following topics shall be addressed in at least one of the public meetings described in paragraph (1):
<br>
<br>(A) An assessment of the steps taken under subsections (b) through (e) to build capacity for a unit-level system, including the impact of the requirements of such subsections on—
<br>
<br>(i) the ability of the health care system collectively to maintain patient access to medicines;
<br>
<br>(ii) the scalability of such requirements, including as it relates to product lines; and
<br>
<br>(iii) the capability of different sectors and subsectors, including both large and small businesses, to affix and utilize the product identifier.
<br>
<br>(B) The system attributes necessary to support the requirements set forth under subsection (g), including the standards necessary for adoption in order to support the secure, interoperable electronic data exchange among sectors within the pharmaceutical distribution supply chain.
<br>
<br>(C) Best practices in each of the different sectors within the pharmaceutical distribution supply chain to implement the requirements of this section.
<br>
<br>(D) The costs and benefits of the implementation of this section, including the impact on each pharmaceutical distribution supply chain sector and on public health.
<br>
<br>(E) Whether electronic tracing requirements, including tracing of product at the package level, are feasible, cost effective, and needed to protect the public health.
<br>
<br>(F) The systems and processes needed to utilize the product identifiers to enhance tracing of product at the package level, including allowing for verification, aggregation, and inference, as necessary.
<br>
<br>(G) The technical capabilities and legal authorities, if any, needed to establish an interoperable, electronic system that provides for tracing of product at the package level.
<br>
<br>(H) The impact that such additional requirements would have on patient safety, the drug supply, cost and regulatory burden, and timely patient access to prescription drugs.
<br>
<br>(I) Other topics, as determined appropriate by the Secretary.
<br>(j) Pilot projects
<br>(1) In general
<br>
<br>The Secretary shall establish 1 or more pilot projects, in coordination with authorized manufacturers, repackagers, wholesale distributors, and dispensers, to explore and evaluate methods to enhance the safety and security of the pharmaceutical distribution supply chain. Such projects shall build upon efforts, in existence as of November 27, 2013, to enhance the safety and security of the pharmaceutical distribution supply chain, take into consideration any pilot projects conducted prior to November 27, 2013, including any pilot projects that use aggregation and inference, and inform the draft and final guidance under paragraphs (3) and (4) of subsection (h).
<br>(2) Content
<br>(A) In general
<br>
<br>The Secretary shall ensure that the pilot projects under paragraph (1) reflect the diversity of the pharmaceutical distribution supply chain and that the pilot projects, when taken as a whole, include participants representative of every sector, including both large and small businesses.
<br>(B) Project design
<br>
<br>The pilot projects under paragraph (1) shall be designed to—
<br>
<br>(i) utilize the product identifier for tracing of a product, which may include verification of the product identifier of a product, including the use of aggregation and inference;
<br>
<br>(ii) improve the technical capabilities of each sector and subsector to comply with systems and processes needed to utilize the product identifiers to enhance tracing of a product;
<br>
<br>(iii) identify system attributes that are necessary to implement the requirements established under this section; and
<br>
<br>(iv) complete other activities as determined by the Secretary.
<br>(k) Sunset
<br>
<br>The following requirements shall have no force or effect beginning on the date that is 10 years after November 27, 2013:
<br>
<br>(1) The provision and receipt of transaction history under this section.
<br>
<br>(2) The requirements set forth for returns under subsections (b)(4)(E), (c)(1)(B)(i), (d)(1)(C)(i), and (e)(4)(E).
<br>
<br>(3) The requirements set forth under subparagraphs (A)(v)(II) and (D) of subsection (c)(1), as applied to lot level information only.
<br>(l) Rule of construction
<br>
<br>The requirements set forth in subsections (g)(4), (i), and (j) shall not be construed as a condition, prohibition, or precedent for precluding or delaying the provisions becoming effective pursuant to subsection (g).
<br>(m) Requests for information
<br>
<br>On the date that is 10 years after November 27, 2013, the timeline for responses to requests for information from the Secretary, or other appropriate Federal or State official, as applicable, under subsections (b)(1)(B), (c)(1)(C), and (e)(1)(C) shall be not later than 24 hours after receiving the request from the Secretary or other appropriate Federal or State official, as applicable, or in such other reasonable time as determined by the Secretary based on the circumstances of the request.
<br>
<br>(June 25, 1938, ch. 675, §582, as added and amended Pub. L. 113–54, title II, §§202, 203, Nov. 27, 2013, 127 Stat. 605, 623.)
<br>
<br>Editorial Notes
<br>Amendments
<br>
<br>2013—Subsecs. (g) to (m). Pub. L. 113–54, §203, added subsecs. (g) to (m).
<br>
<br>1 So in original. Probably should be "title".
<br>
<br>2 So in original. Probably should be "a".
<br>§360eee–2. National standards for prescription drug wholesale distributors
<br>(a) In general
<br>
<br>The Secretary shall, not later than 2 years after November 27, 2013, establish by regulation standards for the licensing of persons under section 353(e)(1) of this title, including the revocation, reissuance, and renewal of such license.
<br>(b) Content
<br>
<br>For the purpose of ensuring uniformity with respect to standards set forth in this section, the standards established under subsection (a) shall apply to all State and Federal licenses described under section 353(e)(1) of this title and shall include standards for the following:
<br>
<br>(1) The storage and handling of prescription drugs, including facility requirements.
<br>
<br>(2) The establishment and maintenance of records of the distributions of such drugs.
<br>
<br>(3) The furnishing of a bond or other equivalent means of security, as follows:
<br>
<br>(A)(i) For the issuance or renewal of a wholesale distributor license, an applicant that is not a government owned and operated wholesale distributor shall submit a surety bond of $100,000 or other equivalent means of security acceptable to the State.
<br>
<br>(ii) For purposes of clause (i), the State or other applicable authority may accept a surety bond in the amount of $25,000 if the annual gross receipts of the previous tax year for the wholesaler is $10,000,000 or less.
<br>
<br>(B) If a wholesale distributor can provide evidence that it possesses the required bond in a State, the requirement for a bond in another State shall be waived.
<br>
<br>(4) Mandatory background checks and fingerprinting of facility managers or designated representatives.
<br>
<br>(5) The establishment and implementation of qualifications for key personnel.
<br>
<br>(6) The mandatory physical inspection of any facility to be used in wholesale distribution within a reasonable time frame from the initial application of the facility and to be conducted by the licensing authority or by the State, consistent with subsection (c).
<br>
<br>(7) In accordance with subsection (d), the prohibition of certain persons from receiving or maintaining licensure for wholesale distribution.
<br>(c) Inspections
<br>
<br>To satisfy the inspection requirement under subsection (b)(6), the Federal or State licensing authority may conduct the inspection or may accept an inspection by the State in which the facility is located, or by a third-party accreditation or inspection service approved by the Secretary or the State licensing such wholesale distributor.
<br>(d) Prohibited persons
<br>
<br>The standards established under subsection (a) shall include requirements to prohibit a person from receiving or maintaining licensure for wholesale distribution if the person—
<br>
<br>(1) has been convicted of any felony for conduct relating to wholesale distribution, any felony violation of subsection (i) or (k) of section 331 of this title, or any felony violation of section 1365 of title 18 relating to product tampering; or
<br>
<br>(2) has engaged in a pattern of violating the requirements of this section, or State requirements for licensure, that presents a threat of serious adverse health consequences or death to humans.
<br>(e) Requirements
<br>
<br>The Secretary, in promulgating any regulation pursuant to this section, shall, notwithstanding section 553 of title 5—
<br>
<br>(1) issue a notice of proposed rulemaking that includes a copy of the proposed regulation;
<br>
<br>(2) provide a period of not less than 60 days for comments on the proposed regulation; and
<br>
<br>(3) provide that the final regulation take effect on the date that is 2 years after the date such final regulation is published.
<br>
<br>(June 25, 1938, ch. 675, §583, as added Pub. L. 113–54, title II, §204(a)(5), Nov. 27, 2013, 127 Stat. 634.)
<br>
<br>Statutory Notes and Related Subsidiaries
<br>Effective Date
<br>
<br>Section effective Jan. 1, 2015, see section 204(c) of Pub. L. 113–54, set out as an Effective Date of 2013 Amendment note under section 353 of this title.
<br>§360eee–3. National standards for third-party logistics providers
<br>(a) Requirements
<br>
<br>No third-party logistics provider in any State may conduct activities in any State unless each facility of such third-party logistics provider—
<br>
<br>(1)(A) is licensed by the State from which the drug is distributed by the third-party logistics provider, in accordance with the regulations promulgated under subsection (d); or
<br>
<br>(B) if the State from which the drug distributed by the third-party logistics provider has not established a licensure requirement, is licensed by the Secretary, in accordance with the regulations promulgated under subsection (d); and
<br>
<br>(2) if the drug is distributed interstate, is licensed by the State into which the drug is distributed by the third-party logistics provider if such State licenses third-party logistics providers that distribute drugs into the State and the third-party logistics provider is not licensed by the Secretary as described in paragraph (1)(B).
<br>(b) Reporting
<br>
<br>Beginning 1 year after November 27, 2013, a facility of a third-party logistics provider shall report to the Secretary, on an annual basis pursuant to a schedule determined by the Secretary—
<br>
<br>(1) the State by which the facility is licensed and the appropriate identification number of such license; and
<br>
<br>(2) the name and address of the facility and all trade names under which such facility conducts business.
<br>(c) Costs
<br>(1) Authorized fees of Secretary
<br>
<br>If a State does not establish a licensing program for a third-party logistics provider, the Secretary shall license the third-party logistics provider located in such State and may collect a reasonable fee in such amount necessary to reimburse the Secretary for costs associated with establishing and administering the licensure program and conducting periodic inspections under this section. The Secretary shall adjust fee rates as needed on an annual basis to generate only the amount of revenue needed to perform this service. Fees authorized under this paragraph shall be collected and available for obligation only to the extent and in the amount provided in advance in appropriations Acts. Such fees are authorized to remain available until expended. Such sums as may be necessary may be transferred from the Food and Drug Administration salaries and expenses appropriation account without fiscal year limitation to such appropriation account for salaries and expenses with such fiscal year limitation.
<br>(2) State licensing fees
<br>(A) State established program
<br>
<br>Nothing in this chapter shall prohibit a State that has established a program to license a third-party logistics provider from collecting fees from a third-party logistics provider for such a license.
<br>(B) No State established program
<br>
<br>A State that does not establish a program to license a third-party logistics provider in accordance with this section shall be prohibited from collecting a State licensing fee from a third-party logistics provider.
<br>(d) Regulations
<br>(1) In general
<br>
<br>Not later than 2 years after November 27, 2013, the Secretary shall issue regulations regarding the standards for licensing under subsection (a), including the revocation and reissuance of such license, to third-party logistics providers under this section.
<br>(2) Content
<br>
<br>Such regulations shall—
<br>
<br>(A) establish a process by which a third-party accreditation program approved by the Secretary shall, upon request by a third-party logistics provider, issue a license to each third-party logistics provider that meets the requirements set forth in this section;
<br>
<br>(B) establish a process by which the Secretary shall issue a license to each third-party logistics provider that meets the requirements set forth in this section if the Secretary is not able to approve a third-party accreditation program because no such program meets the Secretary's requirements necessary for approval of such a third-party accreditation program;
<br>
<br>(C) require that the entity complies with storage practices, as determined by the Secretary for such facility, including—
<br>
<br>(i) maintaining access to warehouse space of suitable size to facilitate safe operations, including a suitable area to quarantine suspect product;
<br>
<br>(ii) maintaining adequate security; and
<br>
<br>(iii) having written policies and procedures to—
<br>
<br>(I) address receipt, security, storage, inventory, shipment, and distribution of a product;
<br>
<br>(II) identify, record, and report confirmed losses or thefts in the United States;
<br>
<br>(III) correct errors and inaccuracies in inventories;
<br>
<br>(IV) provide support for manufacturer recalls;
<br>
<br>(V) prepare for, protect against, and address any reasonably foreseeable crisis that affects security or operation at the facility, such as a strike, fire, or flood;
<br>
<br>(VI) ensure that any expired product is segregated from other products and returned to the manufacturer or repackager or destroyed;
<br>
<br>(VII) maintain the capability to trace the receipt and outbound distribution of a product, and supplies and records of inventory; and
<br>
<br>(VIII) quarantine or destroy a suspect product if directed to do so by the respective manufacturer, wholesale distributor, dispenser, or an authorized government agency;
<br>
<br>(D) provide for periodic inspection by the licensing authority, as determined by the Secretary, of such facility warehouse space to ensure compliance with this section;
<br>
<br>(E) prohibit a facility from having as a manager or designated representative anyone convicted of any felony violation of subsection (i) or (k) of section 331 of this title or any violation of section 1365 of title 18, relating to product tampering;
<br>
<br>(F) provide for mandatory background checks of a facility manager or a designated representative of such manager;
<br>
<br>(G) require a third-party logistics provider to provide the applicable licensing authority, upon a request by such authority, a list of all product manufacturers, wholesale distributors, and dispensers for whom the third-party logistics provider provides services at such facility; and
<br>
<br>(H) include procedures under which any third-party logistics provider license—
<br>
<br>(i) expires on the date that is 3 years after issuance of the license; and
<br>
<br>(ii) may be renewed for additional 3-year periods.
<br>(3) Procedure
<br>
<br>In promulgating the regulations under this subsection, the Secretary shall, notwithstanding section 553 of title 5—
<br>
<br>(A) issue a notice of proposed rulemaking that includes a copy of the proposed regulation;
<br>
<br>(B) provide a period of not less than 60 days for comments on the proposed regulation; and
<br>
<br>(C) provide that the final regulation takes effect upon the expiration of 1 year after the date that such final regulation is issued.
<br>(e) Validity
<br>
<br>A license issued under this section shall remain valid as long as such third-party logistics provider remains licensed consistent with this section. If the Secretary finds that the third-party accreditation program demonstrates that all applicable requirements for licensure under this section are met, the Secretary shall issue a license under this section to a third-party logistics provider receiving accreditation, pursuant to subsection (d)(2)(A).
<br>
<br>(June 25, 1938, ch. 675, §584, as added Pub. L. 113–54, title II, §205, Nov. 27, 2013, 127 Stat. 636.)
<br>§360eee–4. Uniform national policy
<br>(a) Product tracing and other requirements
<br>
<br>Beginning on November 27, 2013, no State or political subdivision of a State may establish or continue in effect any requirements for tracing products through the distribution system (including any requirements with respect to statements of distribution history, transaction history, transaction information, or transaction statement of a product as such product changes ownership in the supply chain, or verification, investigation, disposition, notification, or recordkeeping relating to such systems, including paper or electronic pedigree systems or for tracking and tracing drugs throughout the distribution system) which are inconsistent with, more stringent than, or in addition to, any requirements applicable under section 353(e) of this title or this part (or regulations issued thereunder), or which are inconsistent with—
<br>
<br>(1) any waiver, exception, or exemption pursuant to section 360eee or 360eee–1 of this title; or
<br>
<br>(2) any restrictions specified in section 360eee–1 of this title.
<br>(b) Wholesale distributor and third-party logistics provider standards
<br>(1) In general
<br>
<br>Beginning on November 27, 2013, no State or political subdivision of a State may establish or continue any standards, requirements, or regulations with respect to wholesale prescription drug distributor or third-party logistics provider licensure that are inconsistent with, less stringent than, directly related to, or covered by the standards and requirements applicable under section 353(e) of this title, in the case of a wholesale distributor, or section 360eee–3 of this title, in the case of a third-party logistics provider.
<br>(2) State regulation of third-party logistics providers
<br>
<br>No State shall regulate third-party logistics providers as wholesale distributors.
<br>(3) Administration fees
<br>
<br>Notwithstanding paragraph (1), a State may administer fee collections for effectuating the wholesale drug distributor and third-party logistics provider licensure requirements under sections 353(e), 360eee–2, and 360eee–3 of this title.
<br>(4) Enforcement, suspension, and revocation
<br>
<br>Notwithstanding paragraph (1), a State—
<br>
<br>(A) may take administrative action, including fines, to enforce a requirement promulgated by the State in accordance with section 353(e) of this title or this part;
<br>
<br>(B) may provide for the suspension or revocation of licenses issued by the State for violations of the laws of such State;
<br>
<br>(C) upon conviction of violations of Federal, State, or local drug laws or regulations, may provide for fines, imprisonment, or civil penalties; and
<br>
<br>(D) may regulate activities of licensed entities in a manner that is consistent with product tracing requirements under section 360eee–1 of this title.
<br>(c) Exception
<br>
<br>Nothing in this section shall be construed to preempt State requirements related to the distribution of prescription drugs if such requirements are not related to product tracing as described in subsection (a) or wholesale distributor and third-party logistics provider licensure as described in subsection (b) applicable under section 353(e) of this title or this part (or regulations issued thereunder).
<br>
<br>(June 25, 1938, ch. 675, §585, as added Pub. L. 113–54, title II, §205, Nov. 27, 2013, 127 Stat. 638.)
<br>Part I—Nonprescription Sunscreen and Other Active Ingredients
<br>Termination of Part
<br>
<br>This part to cease to be effective at the end of fiscal year 2022, see section 360fff–8 of this title.
<br>§360fff. Definitions
<br>
<br>In this part—
<br>
<br>(1) the term "Advisory Committee" means the Nonprescription Drug Advisory Committee of the Food and Drug Administration or any successor to such Committee;
<br>
<br>(2) the term "final sunscreen order" means an order published by the Secretary in the Federal Register containing information stating that a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients—
<br>
<br>(A) is GRASE and is not misbranded if marketed in accordance with such order; or
<br>
<br>(B) is not GRASE and is misbranded;
<br>
<br>(3) the term "GRASE" means generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling of a drug as described in section 321(p) of this title;
<br>
<br>(4) the term "GRASE determination" means, with respect to a nonprescription active ingredient or a combination of nonprescription active ingredients, a determination of whether such ingredient or combination of ingredients is GRASE;
<br>
<br>(5) the term "nonprescription" means not subject to section 353(b)(1) of this title;
<br>
<br>(6) the term "pending request" means each request with respect to a nonprescription sunscreen active ingredient submitted under section 330.14 of title 21, Code of Federal Regulations (as in effect on November 26, 2014) for consideration for inclusion in the over-the-counter drug monograph system—
<br>
<br>(A) that was determined to be eligible for such review by publication of a notice of eligibility in the Federal Register prior to November 26, 2014; and
<br>
<br>(B) for which safety and effectiveness data have been submitted to the Secretary prior to November 26, 2014;
<br>
<br>(7) the term "proposed sunscreen order" means an order containing a tentative determination published by the Secretary in the Federal Register containing information proposing that a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients—
<br>
<br>(A) is GRASE and is not misbranded if marketed in accordance with such order;
<br>
<br>(B) is not GRASE and is misbranded; or
<br>
<br>(C) is not GRASE and is misbranded because the data are insufficient to classify such ingredient or combination of ingredients as GRASE and not misbranded and additional information is necessary to allow the Secretary to determine otherwise;
<br>
<br>(8) the term "sponsor" means the person that submitted—
<br>
<br>(A) a request under section 360fff–1 of this title;
<br>
<br>(B) a pending request; or
<br>
<br>(C) any other application subject to this part;
<br>
<br>(9) the term "sunscreen" means a drug containing one or more sunscreen active ingredients; and
<br>
<br>(10) the term "sunscreen active ingredient" means an active ingredient that is intended for application to the skin of humans for purposes of absorbing, reflecting, or scattering ultraviolet radiation.
<br>
<br>(June 25, 1938, ch. 675, §586, as added Pub. L. 113–195, §2(a), Nov. 26, 2014, 128 Stat. 2035.)
<br>
<br>Statutory Notes and Related Subsidiaries
<br>Construction
<br>
<br>Pub. L. 113–195, §2(b), Nov. 26, 2014, 128 Stat. 2045, provided that: "Nothing in the amendment made by this section [enacting this section and sections 360fff–1 to [former] 360fff–5 of this title] shall be construed to—
<br>
<br>"(1) limit the right of a sponsor (as defined in section 586(8) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 360fff(8)], as added by subsection (a)) to request that the Secretary of Health and Human Services convene an advisory committee; or
<br>
<br>"(2) limit the authority of the Secretary of Health and Human Services to meet with a sponsor (as defined in section 586(8) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a))."
<br>§360fff–1. Submission of requests
<br>
<br>Any person may submit a request to the Secretary for a determination of whether a nonprescription sunscreen active ingredient or a combination of nonprescription sunscreen active ingredients, for use under specified conditions, to be prescribed, recommended, or suggested in the labeling thereof (including dosage form, dosage strength, and route of administration) is GRASE and should be included in part 352 of title 21, Code of Federal Regulations (or any successor regulations) concerning nonprescription sunscreen.
<br>
<br>(June 25, 1938, ch. 675, §586A, as added Pub. L. 113–195, §2(a), Nov. 26, 2014, 128 Stat. 2036.)
<br>§360fff–2. Eligibility determinations; data submission; filing
<br>(a) Eligibility determinations
<br>(1) In general
<br>
<br>Not later than 60 calendar days after the date of receipt of a request under section 360fff–1 of this title, the Secretary shall—
<br>
<br>(A) determine, in accordance with paragraph (2), whether the request is eligible for further review under subsection (b) and section 360fff–3 of this title;
<br>
<br>(B) notify the sponsor of the determination of the Secretary; and
<br>
<br>(C) make such determination publicly available in accordance with paragraph (3) and subsection (b)(1).
<br>(2) Criteria for eligibility
<br>(A) In general
<br>
<br>To be eligible for review under subsection (b) and section 360fff–3 of this title, a request shall be for a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients, for use under specified conditions, to be prescribed, recommended, or suggested in the labeling thereof, that—
<br>
<br>(i) is not included in part 352 of title 21, Code of Federal Regulations (or any successor regulations) concerning nonprescription sunscreen; and
<br>
<br>(ii) has been used to a material extent and for a material time under such conditions, as described in section 321(p)(2) of this title.
<br>(B) Establishment of time and extent
<br>
<br>A sponsor shall include in a request under section 360fff–1 of this title the information required under section 330.14 of title 21, Code of Federal Regulations (or any successor regulations) to meet the standard described in subparagraph (A)(ii).
<br>(3) Public availability
<br>(A) Redactions for confidential information
<br>
<br>If a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients is determined under paragraph (1)(A) to be eligible for further review, the Secretary shall make the request publicly available, with redactions for information that is treated as confidential under section 552(b) of title 5, section 1905 of title 18, or section 331(j) of this title.
<br>(B) Identification of confidential information by sponsor
<br>
<br>At the time that a request is made under section 360fff–1 of this title, the sponsor of such request shall identify any information that such sponsor considers to be confidential information described in subparagraph (A).
<br>(C) Confidentiality during eligibility review
<br>
<br>The information contained in a request under section 360fff–1 of this title shall remain confidential during the Secretary's consideration under this section of whether the request is eligible for further review consistent with section 330.14 of title 21, Code of Federal Regulations (or any successor regulations).
<br>(b) Data submission and filing of requests
<br>(1) In general
<br>
<br>In the case of a request under section 360fff–1 of this title that is determined to be eligible under subsection (a) for further review under this section and section 360fff–3 of this title, the Secretary shall, in notifying the public under subsection (a)(1)(C) of such eligibility determination, post the eligibility determination on the Internet website of the Food and Drug Administration, invite the sponsor of such request and any other interested party to submit comments, and provide a period of not less than 45 calendar days for comments in support of or otherwise relating to a GRASE determination, including published and unpublished data and other information related to the safety and efficacy of such request.
<br>(2) Filing determination
<br>
<br>Not later than 60 calendar days after the submission of data and other information described in paragraph (1) by the sponsor, the Secretary shall determine whether the data and other information submitted by the sponsor under this section are sufficiently complete, including being formatted in a manner that enables the Secretary to determine the completeness of such data and information, to enable the Secretary to conduct a substantive review under section 360fff–3 of this title with respect to such request. Not later than 60 calendar days after the submission of data and other information described in paragraph (1) by the sponsor, if the Secretary determines—
<br>
<br>(A) that such data and other information are sufficiently complete, the Secretary shall—
<br>
<br>(i) issue a written notification to the sponsor of the determination to file such request, and make such notification publicly available; and
<br>
<br>(ii) file such request made under section 360fff–1 of this title; or
<br>
<br>(B) that such data and other information are not sufficiently complete, the Secretary shall issue a written notification to the sponsor of the determination to refuse to file the request, which shall include the reasons for the refusal, including why such data and other information are not sufficiently complete, and make such notification publicly available.
<br>(3) Refusal to file a request
<br>(A) Request for meetings; submission of additional data or other information
<br>
<br>If the Secretary refuses to file a request made under section 360fff–1 of this title, the sponsor may—
<br>
<br>(i) within 30 calendar days of receipt of written notification of such refusal, request, in writing, a meeting with the Secretary regarding the filing determination; and
<br>
<br>(ii) submit additional data or other information.
<br>(B) Meetings
<br>(i) In general
<br>
<br>If a sponsor seeks a meeting under subparagraph (A)(i), the Secretary shall convene the meeting within 30 calendar days of the request for such meeting.
<br>(ii) Actions after meeting
<br>
<br>Following any meeting held under clause (i)—
<br>
<br>(I) the Secretary may file the request within 60 calendar days;
<br>
<br>(II) the sponsor may submit additional data or other information; or
<br>
<br>(III) if the sponsor elects, within 120 calendar days, to have the Secretary file the request (with or without amendments to correct any purported deficiencies to the request)—
<br>
<br>(aa) the Secretary shall file the request over protest, not later than 30 calendar days after the sponsor makes such election;
<br>
<br>(bb) at the time of filing, the Secretary shall provide written notification of such filing to the sponsor; and
<br>
<br>(cc) the Secretary shall make such notification publicly available.
<br>(iii) Requests filed over protest
<br>
<br>The Secretary shall not require the sponsor to resubmit a copy of the request for purposes of filing a request filed over protest, as described in clause (ii)(III).
<br>(C) Submissions of additional data or other information
<br>
<br>Within 60 calendar days of any submission of additional data or other information under subparagraph (A)(ii) or (B)(ii)(II), the Secretary shall reconsider the previous determination made under paragraph (2) with respect to the applicable request and make a new determination in accordance with paragraph (2).
<br>(4) Public availability
<br>(A) Redactions for confidential information
<br>
<br>After the period of confidentiality described in subsection (a)(3)(C), the Secretary shall make data and other information submitted in connection with a request under section 360fff–1 of this title publicly available, with redactions for information that is treated as confidential under section 552(b) of title 5, section 1905 of title 18, or section 331(j) of this title.
<br>(B) Identification of confidential information by sponsor
<br>
<br>A person submitting information under this section shall identify at the time of such submission the portions of such information that the person considers to be confidential information described in subparagraph (A).
<br>
<br>(June 25, 1938, ch. 675, §586B, as added Pub. L. 113–195, §2(a), Nov. 26, 2014, 128 Stat. 2036.)
<br>§360fff–3. GRASE determination
<br>(a) Review of new request
<br>(1) Proposed sunscreen order
<br>
<br>In the case of a request under section 360fff–1 of this title, not later than 300 calendar days after the date on which such request is filed under subsection (b)(2)(A) or (b)(3)(B)(ii)(III) of section 360fff–2 of this title, the Secretary—
<br>
<br>(A) may convene a meeting of the Advisory Committee to review such request; and
<br>
<br>(B) shall complete the review of such request and issue a proposed sunscreen order with respect to such request.
<br>(2) Proposed sunscreen order by Commissioner
<br>
<br>If the Secretary does not issue a proposed sunscreen order under paragraph (1)(B) within such 300-day period, the sponsor of such request may notify the Office of the Commissioner of such request and request review by the Office of the Commissioner. If such sponsor so notifies the Office of the Commissioner, the Commissioner shall, not later than 60 calendar days after the date of notification under this paragraph, issue a proposed sunscreen order with respect to such request.
<br>(3) Public comment period
<br>
<br>A proposed sunscreen order issued under paragraph (1)(B) or (2) with respect to a request shall provide for a period of 45 calendar days for public comment.
<br>(4) Meeting
<br>
<br>A sponsor may request, in writing, a meeting with respect to a proposed sunscreen order issued under this subsection and described in subparagraph (B) or (C) of section 360fff(7) of this title, not later than 30 calendar days after the Secretary issues such order. The Secretary shall convene a meeting with such sponsor not later than 45 calendar days after such request for a meeting.
<br>(5) Final sunscreen order
<br>
<br>With respect to a proposed sunscreen order under paragraph (1)(B) or (2)—
<br>
<br>(A) the Secretary shall issue a final sunscreen order—
<br>
<br>(i) in the case of a proposed sunscreen order described in subparagraph (A) or (B) of section 360fff(7) of this title, not later than 90 calendar days after the end of the public comment period under paragraph (3); or
<br>
<br>(ii) in the case of a proposed sunscreen order described in subparagraph (C) of section 360fff(7) of this title, not later than 210 calendar days after the date on which the sponsor submits the additional information requested pursuant to such proposed sunscreen order; or
<br>
<br>(B) if the Secretary does not issue such final sunscreen order within such 90- or 210-calendar-day period, as applicable, the sponsor of such request may notify the Office of the Commissioner of such request and request review by the Office of the Commissioner.
<br>(6) Final sunscreen order by Commissioner
<br>
<br>The Commissioner shall issue a final sunscreen order with respect to a proposed sunscreen order subject to paragraph (5)(B) not later than 60 calendar days after the date of notification under such paragraph.
<br>(b) Review of pending requests
<br>(1) In general
<br>
<br>The review of a pending request shall be carried out by the Secretary in accordance with this subsection.
<br>(2) Inapplicability of sections 360fff–1 and 360fff–2 of this title
<br>
<br>Sections 360fff–1 and 360fff–2 of this title shall not apply with respect to any pending request.
<br>(3) Feedback letters as proposed sunscreen order
<br>
<br>Notwithstanding the requirements of section 360fff(7) of this title, a letter issued pursuant to section 330.14(g) of title 21, Code of Federal Regulations before November 26, 2014, with respect to a pending request, shall be deemed to be a proposed sunscreen order and displayed on the Internet website of the Food and Drug Administration. Notification of the availability of such letter shall be published in the Federal Register not later than 45 calendar days after November 26, 2014.
<br>(4) Proposed sunscreen order
<br>
<br>In the case of a pending request for which the Secretary has not issued a letter pursuant to section 330.14(g) of title 21, Code of Federal Regulations before November 26, 2014, the Secretary shall complete review of such request and, not later than 90 calendar days after November 26, 2014, issue a proposed sunscreen order with respect to such request.
<br>(5) Proposed sunscreen order by Commissioner
<br>
<br>If the Secretary does not issue a proposed sunscreen order under paragraph (4), or the Secretary does not publish a notification of the availability of a letter under paragraph (3), as applicable, the sponsor of such request may notify the Office of the Commissioner of such request and request review by the Office of the Commissioner. The Commissioner shall, not later than 60 calendar days after the date of notification under this paragraph, issue a proposed order with respect to such request.
<br>(6) Public comment period
<br>
<br>A proposed sunscreen order issued under paragraph (4) or (5), or a notification of the availability of a letter under paragraph (3), with respect to a pending request shall provide for a period of 45 calendar days for public comment.
<br>(7) Meeting
<br>(A) In general
<br>
<br>A sponsor may request, in writing, a meeting with respect to a proposed sunscreen order issued under this subsection, including a letter deemed to be a proposed sunscreen order under paragraph (3), not later than 30 calendar days after the Secretary issues such order or the date upon which such feedback letter is deemed to be a proposed sunscreen order, as applicable. The Secretary shall convene a meeting with such sponsor not later than 45 calendar days after the date of such request for a meeting.
<br>(B) Confidential meetings
<br>
<br>A sponsor may request one or more confidential meetings with respect to a proposed sunscreen order, including a letter deemed to be a proposed sunscreen order under paragraph (3), to discuss matters relating to data requirements to support a general recognition of safety and effectiveness involving confidential information and public information related to such proposed sunscreen order, as appropriate. The Secretary shall convene a confidential meeting with such sponsor in a reasonable time period. If a sponsor requests more than one confidential meeting for the same proposed sunscreen order, the Secretary may refuse to grant an additional confidential meeting request if the Secretary determines that such additional confidential meeting is not reasonably necessary for the sponsor to advance its proposed sunscreen order, or if the request for a confidential meeting fails to include sufficient information upon which to base a substantive discussion. The Secretary shall publish a post-meeting summary of each confidential meeting under this subparagraph that does not disclose confidential commercial information or trade secrets. This subparagraph does not authorize the disclosure of confidential commercial information or trade secrets subject to 552(b)(4) 1 of title 5 or section 1905 of title 18.
<br>(8) Advisory Committee
<br>
<br>In the case of a proposed sunscreen order under paragraph (3), (4), or (5), an Advisory Committee meeting may be convened for the purpose of reviewing and providing recommendations regarding the pending request.
<br>(9) Final sunscreen order
<br>
<br>In the case of a proposed sunscreen order under paragraph (3), (4), or (5)—
<br>
<br>(A) the Secretary shall issue a final sunscreen order with respect to the request—
<br>
<br>(i) in the case of a proposed sunscreen order described in subparagraph (A) or (B) of section 360fff(7) of this title, not later than 90 calendar days after the end of the public comment period under paragraph (6); or
<br>
<br>(ii) in the case of a proposed sunscreen order described in subparagraph (C) of section 360fff(7) of this title—
<br>
<br>(I) if the Advisory Committee is not convened under paragraph (8), not later than 210 calendar days after the date on which the sponsor submits the additional information requested pursuant to such proposed sunscreen order, which shall include a rationale for not convening such Advisory Committee; or
<br>
<br>(II) if the Advisory Committee is convened under paragraph (8), not later than 270 calendar days after the date on which the sponsor submits such additional information; or
<br>
<br>(B) if the Secretary does not issue such final sunscreen order within such 90-, 210-, or 270-calendar-day period, as applicable, the sponsor of such request may notify the Office of the Commissioner about such request and request review by the Office of the Commissioner.
<br>(10) Final sunscreen order by Commissioner
<br>
<br>The Commissioner shall issue a final sunscreen order with respect to a proposed sunscreen order subject to paragraph (9)(B) not later than 60 calendar days after the date of notification under such paragraph.
<br>(c) Advisory Committee
<br>
<br>The Secretary shall not be required to—
<br>
<br>(1) convene the Advisory Committee—
<br>
<br>(A) more than once with respect to any request under section 360fff–1 of this title or any pending request; or
<br>
<br>(B) more than twice in any calendar year with respect to the review under this section; or
<br>
<br>(2) submit more than a total of 3 requests under section 360fff–1 of this title or pending requests to the Advisory Committee per meeting.
<br>(d) No delegation
<br>
<br>Any responsibility vested in the Commissioner by subsection (a)(2), (a)(6), (b)(5), or (b)(10) shall not be delegated.
<br>(e) Effect of final sunscreen order
<br>(1) In general
<br>(A) Sunscreen active ingredients determined to be GRASE
<br>
<br>Upon issuance of a final sunscreen order determining that a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients is GRASE and is not misbranded, a sunscreen containing such ingredient or combination of ingredients shall be permitted to be introduced or delivered into interstate commerce for use under the conditions described in such final sunscreen order, in accordance with all requirements applicable to drugs not subject to section 353(b)(1) of this title, for so long as such final sunscreen order remains in effect.
<br>(B) Sunscreen active ingredients determined not to be GRASE
<br>
<br>Upon issuance of a final sunscreen order determining that a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients is not GRASE and is misbranded, a sunscreen containing such ingredient or combination of ingredients shall not be introduced or delivered into interstate commerce, for use under the conditions described in such final sunscreen order, unless an application is approved pursuant to section 355 of this title with respect to a sunscreen containing such ingredient or combination of ingredients, or unless conditions are later established under which such ingredient or combination of ingredients is later determined to be GRASE and not misbranded under the over-the-counter drug monograph system.
<br>(2) Amendments to final sunscreen orders
<br>(A) Amendments at initiative of Secretary
<br>
<br>In the event that information relevant to a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients becomes available to the Secretary after issuance of a final sunscreen order, the Secretary may amend such final sunscreen order by issuing a new proposed sunscreen order under subsection (a)(1) and following the procedures set forth in this section.
<br>(B) Petition to amend final order
<br>
<br>Any interested person may petition the Secretary to amend a final sunscreen order under section 10.30, title 21 Code of Federal Regulations (or any successor regulations). If the Secretary grants any petition under such section, the Secretary shall initiate the process for amending a final sunscreen order by issuing a new proposed sunscreen order under subsection (a)(1) and following the procedures set forth in this section.
<br>(C) Applicability of final orders
<br>
<br>Once the Secretary issues a new proposed sunscreen order to amend a final sunscreen order under subparagraph (A) or (B), such final sunscreen order shall remain in effect and paragraph (3) shall not apply to such final sunscreen order until the Secretary has issued a new final sunscreen order or has determined not to amend the final sunscreen order.
<br>(3) Relationship to orders under section 355h of this title
<br>
<br>A final sunscreen order shall be deemed to be a final order under section 355h of this title.
<br>(f) Exclusivity
<br>(1) In general
<br>
<br>A final sunscreen order shall have the effect of authorizing solely the order requestor (or the licensees, assignees, or successors in interest of such requestor with respect to the subject of such request and listed under paragraph (5)) for a period of 18 months, to market a sunscreen ingredient under this section incorporating changes described in paragraph (2) subject to the limitations under paragraph (4), beginning on the date the requestor (or any licensees, assignees, or successors in interest of such requestor with respect to the subject of such request and listed under paragraph (5)) may lawfully market such sunscreen ingredient pursuant to the order.
<br>(2) Changes described
<br>
<br>A change described in this paragraph is a change subject to an order specified in paragraph (1) that permits a sunscreen to contain an active sunscreen ingredient not previously incorporated in a marketed sunscreen listed in paragraph (3).
<br>(3) Marketed sunscreen
<br>
<br>The marketed sunscreen ingredients described in this paragraph are sunscreen ingredients—
<br>
<br>(A) marketed in accordance with a final monograph for sunscreen drug products set forth at part 352 of title 21, Code of Federal Regulations (as published at 64 Fed. Reg. 27687); or
<br>
<br>(B) marketed in accordance with a final order issued under this section.
<br>(4) Limitations on exclusivity
<br>
<br>Only one 18-month period may be granted per ingredient under paragraph (1).
<br>(5) Listing of licensees, assignees, or successors in interest
<br>
<br>Requestors shall submit to the Secretary at the time when a drug subject to such request is introduced or delivered for introduction into interstate commerce, a list of licensees, assignees, or successors in interest under paragraph (1).
<br>
<br>(June 25, 1938, ch. 675, §586C, as added Pub. L. 113–195, §2(a), Nov. 26, 2014, 128 Stat. 2039; amended Pub. L. 116–136, div. A, title III, §3854(b)(1)–(3), Mar. 27, 2020, 134 Stat. 455, 456.)
<br>
<br>Editorial Notes
<br>Amendments
<br>
<br>2020—Subsec. (b)(7). Pub. L. 116–136, §3854(b)(2), designated existing provisions as subpar. (A), inserted heading, and added subpar. (B).
<br>
<br>Subsec. (e)(3). Pub. L. 116–136, §3854(b)(1), amended par. (3) generally. Prior to amendment, par. (3) related to inclusion of ingredients that are subjects of final orders in the sunscreen monograph.
<br>
<br>Subsec. (f). Pub. L. 116–136, §3854(b)(3), added subsec. (f).
<br>
<br>Statutory Notes and Related Subsidiaries
<br>Review of Nonprescription Sunscreen Active Ingredients
<br>
<br>Pub. L. 116–136, div. A, title III, §3854(a), Mar. 27, 2020, 134 Stat. 454, provided that:
<br>
<br>"(1) Applicability of section 505g for pending submissions.—
<br>
<br>"(A) In general.—A sponsor of a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients that, as of the date of enactment of this Act [Mar. 27, 2020], is subject to a proposed sunscreen order under section 586C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360fff–3) may elect, by means of giving written notification to the Secretary of Health and Human Services within 180 calendar days of the enactment of this Act, to transition into the review of such ingredient or combination of ingredients pursuant to the process set out in section 505G of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355h], as added by section 3851 of this subtitle.
<br>
<br>"(B) Election exercised.—Upon receipt by the Secretary of Health and Human Services of a timely notification under subparagraph (A)—
<br>
<br>"(i) the proposed sunscreen order involved is deemed to be a request for an order under subsection (b) of section 505G of the Federal Food, Drug, and Cosmetic Act, as added by section 3851 of this subtitle; and
<br>
<br>"(ii) such order is deemed to have been accepted for filing under subsection (b)(6)(A)(i) of such section 505G.
<br>
<br>"(C) Election not exercised.—If a notification under subparagraph (A) is not received by the Secretary of Health and Human Services within 180 calendar days of the date of enactment of this Act, the review of the proposed sunscreen order described in subparagraph (A)—
<br>
<br>"(i) shall continue under section 586C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360fff–3); and
<br>
<br>"(ii) shall not be eligible for review under section 505G, added by section 3851 of this subtitle.
<br>
<br>"(2) Definitions.—In this subsection, the terms 'sponsor', 'nonprescription', 'sunscreen active ingredient', and 'proposed sunscreen order' have the meanings given to those terms in section 586 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360fff)."
<br>
<br>1 So in original. Probably should be preceded by "section".
<br>§360fff–4. Guidance; other provisions
<br>(a) Guidance
<br>(1) In general
<br>(A) Draft guidance
<br>
<br>Not later than 1 year after November 26, 2014, the Secretary shall issue draft guidance on the implementation of, and compliance with, the requirements with respect to sunscreen under this part, including guidance on—
<br>
<br>(i) the format and content of information submitted by a sponsor in support of a request under section 360fff–1 of this title or a pending request;
<br>
<br>(ii) the data required to meet the safety and efficacy standard for determining whether a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients is GRASE and is not misbranded;
<br>
<br>(iii) the process by which a request under section 360fff–1 of this title or a pending request is withdrawn; and
<br>
<br>(iv) the process by which the Secretary will carry out section 360fff–3(c) of this title, including with respect to how the Secretary will address the total number of requests received under section 360fff–1 of this title and pending requests.
<br>(B) Final guidance
<br>
<br>The Secretary shall finalize the guidance described in subparagraph (A) not later than 2 years after November 26, 2014.
<br>(C) Inapplicability of Paperwork Reduction Act
<br>
<br>Chapter 35 of title 44 shall not apply to collections of information made for purposes of guidance under this subsection.
<br>(2) Submissions pending issuance of final guidance
<br>
<br>Irrespective of whether final guidance under paragraph (1) has been issued—
<br>
<br>(A) persons may, beginning on November 26, 2014, make submissions under this part; and
<br>
<br>(B) the Secretary shall review and act upon such submissions in accordance with this part.
<br>(b) Rules of construction
<br>(1) Currently marketed sunscreens
<br>
<br>Nothing in this part shall be construed to affect the marketing of sunscreens that are marketed in interstate commerce on or before November 26, 2014, except as otherwise provided in this part.
<br>(2) Ensuring safety and effectiveness
<br>
<br>Nothing in this part shall be construed to alter the authority of the Secretary with respect to prohibiting the marketing of a sunscreen that is not safe and effective or is misbranded, or with respect to imposing restrictions on the marketing of a sunscreen to ensure safety and effectiveness, except as otherwise provided in this part, including section 360fff–3(e) of this title.
<br>(3) Other drugs
<br>
<br>Except as otherwise provided in section 360fff–6 of this title, nothing in this part shall be construed to affect the authority of the Secretary under this chapter or the Public Health Service Act (42 U.S.C. 201 et seq.) with respect to a drug other than a nonprescription sunscreen.
<br>(4) Effect on drugs otherwise approved
<br>
<br>Nothing in this part shall affect the marketing of a drug approved under section 355 of this title or section 351 of the Public Health Service Act [42 U.S.C. 262].
<br>(c) Timelines
<br>
<br>The timelines for the processes and procedures under paragraphs (1), (2), (5), and (6) of section 360fff–3(a) of this title shall not apply to any requests submitted to the Secretary under section 360fff–1 of this title after the date that is 6 years after November 26, 2014.
<br>
<br>(June 25, 1938, ch. 675, §586D, as added Pub. L. 113–195, §2(a), Nov. 26, 2014, 128 Stat. 2044.)
<br>
<br>Editorial Notes
<br>References in Text
<br>
<br>The Public Health Service Act, referred to in subsec. (b)(3), is act July 1, 1944, ch. 373, 58 Stat. 682, which is classified generally to chapter 6A (§201 et seq.) of Title 42, The Public Health and Welfare. For complete classification of this Act to the Code, see Short Title note set out under section 201 of Title 42 and Tables.
<br>§360fff–5. Repealed. Pub. L. 116–136, div. A, title III, §3854(b)(5), Mar. 27, 2020, 134 Stat. 456
<br>
<br>Section, June 25, 1938, ch. 675, §586E, as added Pub. L. 113–195, §2(a), Nov. 26, 2014, 128 Stat. 2045, related to sunscreen monograph.
<br>§360fff–6. Non-sunscreen time and extent applications
<br>(a) Pending time and extent applications
<br>(1) In general
<br>(A) Request for framework for review
<br>
<br>If, prior to November 26, 2014, an application was submitted pursuant to section 330.14 of title 21, Code of Federal Regulations for a GRASE determination for a drug other than a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients and such drug was found to be eligible to be considered for inclusion in the over-the-counter drug monograph system pursuant to section 330.14 of title 21, Code of Federal Regulations, the sponsor of such application may request that the Secretary provide a framework under paragraph (2) for the review of such application.
<br>(B) Request requirements
<br>
<br>A request for a framework for review of an application made under subparagraph (A) shall be made within 180 calendar days of November 26, 2014, and shall include the preference of such sponsor as to whether such application is reviewed by the Secretary in accordance with—
<br>
<br>(i) the processes and procedures set forth for pending requests under section 360fff–3(b) of this title, except that specific timelines shall be determined in accordance with other applicable requirements under this section;
<br>
<br>(ii) the processes and procedures set forth under part 330 of title 21, Code of Federal Regulations (or any successor regulations);
<br>
<br>(iii) an initial filing determination under the processes and procedures described in section 360fff–2(b) of this title and the processes and procedures set forth for pending requests under section 360fff–3(b) of this title, except that specific timelines shall be determined in accordance with other applicable requirements under this section; or
<br>
<br>(iv) an initial filing determination under the processes and procedures described in section 360fff–2(b) of this title and the processes and procedures set forth under part 330 of title 21, Code of Federal Regulations (or any successor regulations).
<br>(C) No request
<br>
<br>If a sponsor described in subparagraph (A) does not make such request within 180 calendar days of November 26, 2014, such application shall be reviewed by the Secretary in accordance with the timelines of the applicable regulations when such regulations are finalized under subsection (b).
<br>(2) Framework
<br>
<br>Not later than 1 year after November 26, 2014, the Secretary shall provide, in writing, a framework to each sponsor that submitted a request under paragraph (1). Such framework shall set forth the various timelines, in calendar days, with respect to the processes and procedures for review under clauses (i), (ii), (iii), and (iv) of paragraph (1)(B) and—
<br>
<br>(A) such timelines shall account for the considerations under paragraph (5); and
<br>
<br>(B) the timelines for the various processes and procedures shall not be shorter than the timelines set forth for pending requests under sections 360fff–2(b) and 360fff–3(b) of this title, as applicable.
<br>(3) Governing processes and procedures for review
<br>(A) Election
<br>
<br>Not later than 60 calendar days after the Secretary provides a framework to a sponsor under paragraph (2), such sponsor may provide an election to the Secretary regarding the processes and procedures for review under clause (i), (ii), (iii), or (iv) of paragraph (1)(B). If such sponsor makes such election, the Secretary shall review the application that is the subject of such election pursuant to the processes and procedures elected by such sponsor and the applicable timelines in calendar days set forth under such framework, which the Secretary shall confirm in writing to the sponsor not later than the date upon which the Secretary provides a report under paragraph (4). If such sponsor does not make such election, such application shall be reviewed by the Secretary in accordance with the timelines of the applicable regulations when such regulations are finalized under subsection (b).
<br>(B) Different processes and procedures
<br>
<br>At any time during review of an application, the Secretary may review such application under different processes and procedures under clause (i), (ii), (iii), or (iv) of paragraph (1)(B) than the processes and procedures the sponsor elected in accordance with subparagraph (A), so long as the Secretary proposes, in writing, the change and the sponsor agrees, in writing, to such change.
<br>(C) Inclusion of ingredients in monographs
<br>
<br>If the sponsor elects to use the processes and procedures for review in accordance with clause (i) or (iii) of paragraph (1)(B), the Secretary may incorporate any resulting final order into a regulation addressing the conditions under which other drugs in the same therapeutic category are GRASE and not misbranded, including through direct final rulemaking, and the final order so incorporated shall cease to be effective on the effective date of the final regulation that addresses such drug.
<br>(4) Letter regarding pending applications
<br>
<br>Not later than 18 months after November 26, 2014, the Secretary shall report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, in writing, regarding all pending applications subject to paragraph (1). In such letter, the Secretary shall provide a report on the review of such applications, including the timelines, in calendar days, for the review and GRASE determination for each application. Such timelines shall account for the considerations under paragraph (5).
<br>(5) Timelines
<br>
<br>The timelines in calendar days established by the Secretary pursuant to this subsection—
<br>
<br>(A) may vary based on the content, complexity, and format of the application submitted to the Secretary; and
<br>
<br>(B) shall—
<br>
<br>(i) reflect the public health priorities of the Food and Drug Administration, including the potential public health benefits posed by the inclusion of additional drugs in the over-the-counter drug monograph system;
<br>
<br>(ii) take into consideration the resources available to the Secretary for carrying out such priorities and the processes and procedures described in paragraphs (1)(B) and (2); and
<br>
<br>(iii) be reasonable, taking into consideration the requirements described in clauses (i) and (ii).
<br>(b) New time and extent applications
<br>(1) In general
<br>
<br>Not later than 18 months after November 26, 2014, the Secretary shall issue proposed regulations establishing timelines for the review of applications for GRASE determinations for drugs other than nonprescription sunscreen active ingredients or combinations of nonprescription sunscreen active ingredients that are submitted to the Secretary after November 26, 2014, under section 330.14 of title 21, Code of Federal Regulations (or any successor regulations), and that are found to be eligible to be considered for inclusion in the over-the-counter drug monograph system pursuant to section 330.14 of title 21, Code of Federal Regulations (or any successor regulations), or that are subject to this subsection pursuant to paragraph (1) or (3) of subsection (a), as applicable, providing—
<br>
<br>(A) timely and efficient completion of evaluations of applications under section 330.14 of title 21, Code of Federal Regulations (or any successor regulations) for drugs other than sunscreens; and
<br>
<br>(B) timely and efficient completion of the review of the safety and effectiveness submissions pursuant to such applications, including establishing—
<br>
<br>(i) reasonable timelines, in calendar days, for the applicable proposed and final regulations for applications of various content, complexity, and format, and timelines for internal procedures related to such processes; and
<br>
<br>(ii) measurable metrics for tracking the extent to which the timelines set forth in the regulations are met.
<br>(2) Timelines
<br>
<br>The timelines in calendar days established in the regulations under paragraph (1)—
<br>
<br>(A) may vary based on the content, complexity, and format of the application submitted to the Secretary; and
<br>
<br>(B) shall—
<br>
<br>(i) reflect the public health priorities of the Food and Drug Administration, including the potential public health benefits posed by the inclusion of additional drugs in the over-the-counter drug monograph system;
<br>
<br>(ii) take into consideration the resources available to the Secretary for carrying out such priorities and the processes and procedures described in paragraph (1); and
<br>
<br>(iii) be reasonable, taking into consideration the requirements described in clauses (i) and (ii).
<br>(3) Procedure
<br>
<br>In promulgating regulations under this subsection, the Secretary shall issue a notice of proposed rulemaking that includes a copy of the proposed regulation, provide a period of not less than 60 calendar days for comments on the proposed regulation, and publish the final regulation not less than 30 calendar days before the effective date of the regulation.
<br>(4) Restrictions
<br>
<br>Notwithstanding any other provision of law, the Secretary shall promulgate regulations implementing this section only as described in paragraphs (1), (2), and (3).
<br>(5) Final regulations
<br>
<br>The Secretary shall finalize the regulations under this section not later than 27 months after November 26, 2014.
<br>
<br>(June 25, 1938, ch. 675, §586F, as added Pub. L. 113–195, §3, Nov. 26, 2014, 128 Stat. 2046.)
<br>
<br>Statutory Notes and Related Subsidiaries
<br>Treatment of Non-Sunscreen Time and Extent Applications
<br>
<br>Pub. L. 116–136, div. A, title III, §3854(d), Mar. 27, 2020, 134 Stat. 457, provided that:
<br>
<br>"(1) In general.—Any application described in section 586F of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360fff–6) that was submitted to the Secretary pursuant to section 330.14 of title 21, Code of Federal Regulations, as such provisions were in effect immediately prior to the date of enactment date of this Act [Mar. 27, 2020], shall be extinguished as of such date of enactment, subject to paragraph (2).
<br>
<br>"(2) Order request.—Nothing in paragraph (1) precludes the submission of an order request under section 505G(b) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355h(b)], as added by section 3851 of this subtitle, with respect to a drug that was the subject of an application extinguished under paragraph (1)."
<br>§360fff–7. Report
<br>(a) In general
<br>(1) In general
<br>
<br>Not later than 18 months after November 26, 2014, and on the dates that are 2 and 4 years thereafter, the Secretary shall issue a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives describing actions taken under this part.
<br>(2) Contents
<br>
<br>The reports under this subsection shall include—
<br>
<br>(A) a review of the progress made in issuing GRASE determinations for pending requests, including the number of pending requests—
<br>
<br>(i) reviewed and the decision times for each request, measured from the date of the original request for an eligibility determination submitted by the sponsor;
<br>
<br>(ii) resulting in a determination that the nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients is GRASE and is not misbranded;
<br>
<br>(iii) resulting in a determination that the nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients is not GRASE and is misbranded and the reasons for such determinations; and
<br>
<br>(iv) for which a determination has not been made, and an explanation for the delay, a description of the current status of each such request, and the length of time each such request has been pending, measured from the date of original request for an eligibility determination by the sponsor;
<br>
<br>(B) a review of the progress made in issuing GRASE determinations for requests not included in the reporting under subparagraph (A), including the number of such requests—
<br>
<br>(i) reviewed and the decision times for each request;
<br>
<br>(ii) resulting in a determination that the nonprescription sunscreen active ingredient, combination of nonprescription sunscreen active ingredients, or other ingredient is GRASE and is not misbranded;
<br>
<br>(iii) resulting in a determination that the nonprescription sunscreen active ingredient, combination of nonprescription sunscreen active ingredients, or other ingredient is not GRASE and is misbranded and the reasons for such determinations; and
<br>
<br>(iv) for which a determination has not been made, and an explanation for the delay, a description of the current status of each such request, and the length of time each such request has been pending, measured from the date of original request for an eligibility determination by the sponsor;
<br>
<br>(C) an annual accounting (including information from years prior to November 26, 2014, where such information is available) of the total number of requests submitted, pending, or completed under this part, including whether such requests were the subject of an advisory committee convened by the Secretary;
<br>
<br>(D) a description of the staffing and resources relating to the costs associated with the review and decisionmaking pertaining to requests under this part;
<br>
<br>(E) a review of the progress made in meeting the deadlines with respect to processing requests under this part; and
<br>
<br>(F) to the extent the Secretary determines appropriate, recommendations for process improvements in the handling of requests under this part, including the advisory committee review process.
<br>(b) Method
<br>
<br>The Secretary shall publish the reports under subsection (a) in the manner the Secretary determines to be the most effective for efficiently disseminating the report, including publication of the report on the Internet website of the Food and Drug Administration.
<br>
<br>(June 25, 1938, ch. 675, §586G, as added Pub. L. 113–195, §4(c), Nov. 26, 2014, 128 Stat. 2050.)
<br>§360fff–8. Sunset
<br>
<br>This part shall cease to be effective at the end of fiscal year 2022.
<br>
<br>(June 25, 1938, ch. 675, §586H, as added Pub. L. 116–136, div. A, title III, §3854(b)(4), Mar. 27, 2020, 134 Stat. 456.)
<br>SUBCHAPTER VI—COSMETICS
<br>§361. Adulterated cosmetics
<br>
<br>A cosmetic shall be deemed to be adulterated—
<br>
<br>(a) If it bears or contains any poisonous or deleterious substance which may render it injurious to users under the conditions of use prescribed in the labeling thereof, or under such conditions of use as are customary or usual, except that this provision shall not apply to coal-tar hair dye, the label of which bears the following legend conspicuously displayed thereon: "Caution—This product contains ingredients which may cause skin irritation on certain individuals and a preliminary test according to accompanying directions should first be made. This product must not be used for dyeing the eyelashes or eyebrows; to do so may cause blindness.", and the labeling of which bears adequate directions for such preliminary testing. For the purposes of this paragraph and paragraph (e) the term "hair dye" shall not include eyelash dyes or eyebrow dyes.
<br>
<br>(b) If it consists in whole or in part of any filthy, putrid, or decomposed substance.
<br>
<br>(c) If it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health.
<br>
<br>(d) If its container is composed, in whole or in part, of any poisonous or deleterious substance which may render the contents injurious to health.
<br>
<br>(e) If it is not a hair dye and it is, or it bears or contains, a color additive which is unsafe within the meaning of section 379e(a) of this title.
<br>
<br>(June 25, 1938, ch. 675, §601, 52 Stat. 1054; Pub. L. 86–618, title I, §102(c)(1), July 12, 1960, 74 Stat. 398; Pub. L. 102–571, title I, §107(11), Oct. 29, 1992, 106 Stat. 4499; Pub. L. 103–80, §3(x), Aug. 13, 1993, 107 Stat. 778.)
<br>
<br>Editorial Notes
<br>Amendments
<br>
<br>1993—Subsec. (a). Pub. L. 103–80 substituted "usual, except that this" for "usual: Provided, That this".
<br>
<br>1992—Par. (e). Pub. L. 102–571 substituted "379e(a)" for "376(a)".
<br>
<br>1960—Par. (e). Pub. L. 86–618 substituted "and it is, or it bears or contains, a color additive which is unsafe within the meaning of section 376(a) of this title" for "and it bears or contains a coal-tar color other than one from a batch that has been certified in accordance with regulations as provided by section 364 of this title".
<br>
<br>Statutory Notes and Related Subsidiaries
<br>Effective Date of 1960 Amendment
<br>
<br>Amendment by Pub. L. 86–618 effective July 12, 1960, subject to the provisions of section 203 of Pub. L. 86–618, see section 202 of Pub. L. 86–618, set out as a note under section 379e of this title.
<br>Effective Date; Postponement
<br>
<br>Par. (e) effective Jan. 1, 1940, see act June 23, 1939, ch. 242, 53 Stat. 853, set out as an Effective Date; Postponement in Certain Cases note under section 301 of this title.
<br>Effective Date
<br>
<br>Section effective twelve months after June 25, 1938, except par. (a), which, with certain exceptions, became effective on June 25, 1938, see section 1002(a) of act June 25, 1938, set out as a note under section 301 of this title.
<br>§362. Misbranded cosmetics
<br>
<br>A cosmetic shall be deemed to be misbranded—
<br>
<br>(a) If its labeling is false or misleading in any particular.
<br>
<br>(b) If in package form unless it bears a label containing (1) the name and place of business of the manufacturer, packer, or distributor; and (2) an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count: Provided, That under clause (2) of this paragraph reasonable variations shall be permitted, and exemptions as to small packages shall be established, by regulations prescribed by the Secretary.
<br>
<br>(c) If any word, statement, or other information required by or under authority of this chapter to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.
<br>
<br>(d) If its container is so made, formed, or filled as to be misleading.
<br>
<br>(e) If it is a color additive, unless its packaging and labeling are in conformity with such packaging and labeling requirements, applicable to such color additive, as may be contained in regulations issued under section 379e of this title. This paragraph shall not apply to packages of color additives which, with respect to their use for cosmetics, are marketed and intended for use only in or on hair dyes (as defined in the last sentence of section 361(a) of this title).
<br>
<br>(f) If its packaging or labeling is in violation of an applicable regulation issued pursuant to section 1472 or 1473 of title 15.
<br>
<br>(June 25, 1938, ch. 675, §602, 52 Stat. 1054; Pub. L. 86–618, title I, §102(c)(2), July 12, 1960, 74 Stat. 398; Pub. L. 91–601, §6(f), formerly §7(f), Dec. 30, 1970, 84 Stat. 1673, renumbered Pub. L. 97–35, title XII, §1205(c), Aug. 13, 1981, 95 Stat. 716; Pub. L. 102–571, title I, §107(12), Oct. 29, 1992, 106 Stat. 4499.)
<br>
<br>Editorial Notes
<br>Amendments
<br>
<br>1992—Par. (e). Pub. L. 102–571 substituted "379e" for "376".
<br>
<br>1970—Par. (f). Pub. L. 91–601 added par. (f).
<br>
<br>1960—Par. (e). Pub. L. 86–618 added par. (e).
<br>
<br>Statutory Notes and Related Subsidiaries
<br>Effective Date of 1970 Amendment
<br>
<br>Amendment by Pub. L. 91–601 effective Dec. 30, 1970, and regulations establishing special packaging standards effective no sooner than 180 days or later than one year from date regulations are final, or an earlier date published in Federal Register, see section 8 of Pub. L. 91–601, set out as an Effective Date note under section 1471 of Title 15, Commerce and Trade.
<br>Effective Date of 1960 Amendment
<br>
<br>Amendment by Pub. L. 86–618 effective July 12, 1960, subject to the provisions of section 203 of Pub. L. 86–618, see section 202 of Pub. L. 86–618, set out as a note under section 379e of this title.
<br>Effective Date; Postponement
<br>
<br>Par. (b) effective Jan. 1, 1940, and such subsection effective July 1, 1940, as provided by regulations for certain lithographed labeling and containers bearing certain labeling, see act June 23, 1939, ch. 242, 53 Stat. 853, set out as an Effective Date; Postponement in Certain Cases note under section 301 of this title.
<br>Transfer of Functions
<br>
<br>For transfer of functions of Federal Security Administrator to Secretary of Health, Education, and Welfare [now Health and Human Services], and of Food and Drug Administration in the Department of Agriculture to Federal Security Agency, see notes set out under section 321 of this title.
<br>§363. Regulations making exemptions
<br>
<br>The Secretary shall promulgate regulations exempting from any labeling requirement of this chapter cosmetics which are, in accordance with the practice of the trade, to be processed, labeled, or repacked in substantial quantities at establishments other than those where originally processed or packed, on condition that such cosmetics are not adulterated or misbranded under the provisions of this chapter upon removal from such processing, labeling, or repacking establishment.
<br>
<br>(June 25, 1938, ch. 675, §603, 52 Stat. 1054.)
<br>
<br>Statutory Notes and Related Subsidiaries
<br>Transfer of Functions
<br>
<br>For transfer of functions of Federal Security Administrator to Secretary of Health, Education, and Welfare [now Health and Human Services], and of Food and Drug Administration in the Department of Agriculture to Federal Security Agency, see notes set out under section 321 of this title.
<br>§364. Repealed. Pub. L. 86–618, title I, §103(a)(3), July 12, 1960, 74 Stat. 398
<br>
<br>Section, act June 25, 1938, ch. 675, §604, 52 Stat. 1055, directed Secretary to promulgate regulations for listing of coal-tar colors for cosmetics. See section 379e of this title.
<br>
<br><br><a href="Rules-1095.html">Next page</a> 
<a href="Rules-1093.html">Previous page</a>
<br><br><a href="index.html">Home</a>
